German conglomerate Bayer AG (BAYRY.PK,BAYZF.PK) on Wednesday said it sees good perspectives for its businesses in the medium term.
At the "Meet Management" investor conference on Wednesday in Leverkusen, CEO Marijn Dekkers said, "In the life science areas - HealthCare and CropScience - we anticipate further increases in sales and margins through 2014."
The company expects sales of Bayer HealthCare to reach approximately 20 billion euros in 2014, while Bayer CropScience aims to raise sales to more than 8 billion euros.
Bayer added that its MaterialScience segment intends to further strengthen its leading position in the market and plans to achieve volume gains in excess of the rate of global GDP growth.
Dekkers added that the main reason for the optimistic outlook for HealthCare subgroup is its well-stocked development pipeline in Pharmaceuticals. "We believe four of our medicines in late-stage development have blockbuster potential. That means each of these products could achieve peak annual sales of EUR 1 billion or more," he added.
The company added that it aims to successfully commercialize the late-stage pharmaceutical pipeline and take advantage of business opportunities in the emerging markets.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org